Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01743521
Registration number
NCT01743521
Ethics application status
Date submitted
28/11/2012
Date registered
6/12/2012
Date last updated
29/03/2017
Titles & IDs
Public title
DAA Based Therapy for Recently Acquired Hepatitis C (DARE-C)
Query!
Scientific title
Direct Acting Antiviral (DAA) Based Therapy for Recently Acquired Hepatitis C
Query!
Secondary ID [1]
0
0
VX-950HCP4010
Query!
Secondary ID [2]
0
0
VHCRP1102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DARE-C
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Hepatitis C, Chronic
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Oral and Gastrointestinal
0
0
0
0
Query!
Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - TPV/PEG-IFN/RBV
Experimental: Group A - 8 weeks total therapy - 8 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 2 weeks of therapy
Experimental: Group B - 12 weeks total therapy - 12 weeks total therapy of TPV/PEG-IFN/RBV if undetectable HCV RNA after 4 weeks of therapy
Experimental: Group C - 24 weeks total therapy - 24 weeks total therapy - TPV/PEG-IFN/RBV for 12 weeks + PEG-IFN/RBV for 12 weeks if undetectable HCV RNA after 8 weeks of therapy
Treatment: Drugs: TPV/PEG-IFN/RBV
Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.
Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing = 75kg).
Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
SVR12 (Sustain Virological Response, HCV RNA Undetectable 12 Weeks Post-treatment)
Query!
Assessment method [1]
0
0
Proportion of subjects achieving SVR 12 (negative qualitative HCV RNA 12 weeks after therapy completion)
Query!
Timepoint [1]
0
0
12 weeks post-treatment
Query!
Secondary outcome [1]
0
0
SVR24
Query!
Assessment method [1]
0
0
To evaluate the proportion of patients with undetectable HCV RNA 24 weeks after therapy completion (SVR24)
Query!
Timepoint [1]
0
0
24 weeks post-treatment
Query!
Secondary outcome [2]
0
0
Undetectable HCV RNA (ETR)
Query!
Assessment method [2]
0
0
To evaluate the proportion of patients with undetectable HCV RNA at end of treatment (ETR)
Query!
Timepoint [2]
0
0
Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [3]
0
0
Undetectable HCV RNA (Week 1)
Query!
Assessment method [3]
0
0
To evaluate the proportion of patients with undetectable HCV RNA at week 1 of therapy.
Query!
Timepoint [3]
0
0
Week 1 of therapy
Query!
Secondary outcome [4]
0
0
Undectectable HCV RNA (Week 2)
Query!
Assessment method [4]
0
0
To evaluate the proportion of patients with undetectable HCV RNA at week 1 of therapy.
Query!
Timepoint [4]
0
0
Week 2 of therapy
Query!
Secondary outcome [5]
0
0
Undetectable HCV RNA (Week 3)
Query!
Assessment method [5]
0
0
To evaluate the proportion of patients with undetectable HCV RNA at week 3 of therapy.
Query!
Timepoint [5]
0
0
Week 3 of therapy
Query!
Secondary outcome [6]
0
0
Undetectable HCV RNA (Week 4)
Query!
Assessment method [6]
0
0
To evaluate the proportion of patients with undetectable HCV RNA at week 4 of therapy.
Query!
Timepoint [6]
0
0
Week 4 of therapy
Query!
Secondary outcome [7]
0
0
Decrease in Absolute Neutrophil Count (ANC) =0.75
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [8]
0
0
Decrease in Platelets <50
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [9]
0
0
Change in Hemoglobin at End of Treatment
Query!
Assessment method [9]
0
0
To evaluate indicators of toxicity during telaprevir based therapy
Query!
Timepoint [9]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [10]
0
0
Resistance-associated Variants
Query!
Assessment method [10]
0
0
To examine the emergence of resistance-associated variants during telaprevir based therapy for early chronic infection
Query!
Timepoint [10]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [11]
0
0
Baseline Resistance-associated Variants
Query!
Assessment method [11]
0
0
To correlate the presence and frequency of baseline resistance-associated variants (RAVs) with the response of Telaprevir based therapy for early chronic HCV infection.
Query!
Timepoint [11]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [12]
0
0
Plasma Ribavirin Levels
Query!
Assessment method [12]
0
0
To correlate plasma ribavirin levels with treatment outcome and changes in haemoglobin during therapy
Query!
Timepoint [12]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [13]
0
0
CD4 and HIV RNA
Query!
Assessment method [13]
0
0
In HIV positive participants to evaluate changes in CD4 counts and HIV RNA during telaprevir based therapy
Query!
Timepoint [13]
0
0
Baseline, Wk 8 (Group A), Wk 12 (Group B), Wk 24 (Group C)
Query!
Secondary outcome [14]
0
0
Gene IL28B Polymorphism
Query!
Assessment method [14]
0
0
To examine treatment outcome by IL28B polymorphism
Query!
Timepoint [14]
0
0
Baseline
Query!
Eligibility
Key inclusion criteria
1. Provision of written, informed consent.
2. HCV genotype 1 infection
3. Quantifiable HCV RNA at screening and baseline (>10,000 IU/ml)
4. Recent hepatitis C infection with an estimated duration of Infection >6 months and =
18 months defined as A) i) First anti-HCV antibody or HCV RNA positive within the
previous 6 months and ii) Documented anti-HCV antibody negative or HCV RNA negative
within the 24 months prior to anti-HCV antibody positive result OR B) i) First
anti-HCV antibody or HCV RNA positive within the previous 6 months and ii) acute
clinical hepatitis (jaundice or ALT> 10 X ULN) within the 12 months prior to first
positive HCV antibody or HCV RNA with no other cause of acute hepatitis identifiable
5. Compensated liver disease (Child-Pugh A)
6. Negative pregnancy test at screening and 24 hours prior to the first dose of study
drugs.
7. If heterosexually active, a female subject of childbearing potential and a
nonvasectomized male subject who has a female partner of childbearing potential must
agree to use 2 effective contraceptives from screening onwards until 6 months (female
subject) or 7 months (male subject) after RBV therapy has ended. Note: Hormonal
contraceptives may be continued but may not be reliable during telaprevir dosing and
for 2 months following cessation of telaprevir. Therefore, subjects should agree to
use 2 effective non-hormonal methods of contraception during telaprevir combination
therapy and for 2 months after the last intake of telaprevir. As of two months after
completion of telaprevir hormonal contraceptives can again be used as one of the two
required effective methods of birth control.
8. Subject is judged to be medically stable on the basis of physical examination, medical
history and vital signs.
9. Adequate English to provide written, informed consent and to provide reliable
responses to the study interview
Additional inclusion criteria for HIV positive individuals
- Confirmed HIV infection > 6 months duration
- CD4 > 200 cells/mm3 and HIV < 50 c/ml on stable antiretroviral therapy (ART) at least
3 months prior to treatment
- Or
- CD4 >= 500 cells/mm3 and HIV viral load (VL) < 100,000 not on ART
- If on ART must be taking a regimen containing an accepted* combination of the
following drugs: tenofovir ( TDF), lamivudine ( 3TC), emtricitabine (FTC), efavirenz
(EFV), abacavir (ABC), raltegravir (RAL), etravirine (ETV), rilpivirine (RIL),
ritonavir boosted atazanavir (r/ATZ) * Combination must be supported by current HIV
treatment guidelines
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
60
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Individuals considered by the study investigators to be unlikely to participate in
intensive follow-up and/or unwilling to provide extra blood samples
- Current injecting drug use (any injecting within previous 4 weeks)
- Standard exclusions to Pegylated-interferon (PEG-IFN), Ribavirin (RBV) and Telaprevir
(TPV) therapy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 4
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/01/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/01/2016
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
14
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA
Query!
Recruitment hospital [1]
0
0
St Vincent's Hospital - Sydney
Query!
Recruitment hospital [2]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment postcode(s) [1]
0
0
2010 - Sydney
Query!
Recruitment postcode(s) [2]
0
0
5000 - Adelaide
Query!
Funding & Sponsors
Primary sponsor type
Other
Query!
Name
Kirby Institute
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Janssen-Cilag Ltd.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To examine the safety and efficacy of response guided triple therapy (PEG-IFN, Ribavirin,
Telaprevir) for the treatment of early chronic Hepatitis C Virus (HCV) infection.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01743521
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Gail Matthews, MbChB, PhD
Query!
Address
0
0
Kirby Institute
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01743521
Download to PDF